Related Experiment Videos
Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies
A Chott1, H Gisslinger, J Thiele
1Department of Pathology, University of Vienna, Austria.
Abstract:
Interferon(rIFN)-alpha, a successful therapeutic agent in the control of thrombocytosis, has been shown to suppress human megakaryopoiesis. We investigated bone marrow biopsies from 12 patients with thrombocytosis due to chronic myeloproliferative disorders. Prior to treatment as well as during rIFN-alpha-2c therapy, several morphometric parameters of megakaryopoiesis were evaluated. Megakaryocyte density decreased significantly in all patients, megakaryocyte size decreased in polycythaemia vera, agnogenic myeloid metaplasia, and essential thrombocythaemia, but increased in chronic myeloid leukaemia. The various changes observed during therapy indicate an inhibitory effect of rIFN-alpha-2c on megakaryopoiesis and suggest a selective influence on megakaryocytes at various stages of maturation. Increased numbers of pyknotic (bare) nuclei may reflect a shortening of megakaryocyte life-span. No remarkable changes were found in the fibre content of the bone marrow.
Insights
Recombinant interferon-alpha (rIFN)-alpha-2c therapy significantly impacts megakaryopoiesis in patients with chronic myeloproliferative disorders. This treatment suppresses megakaryocyte density and alters cell size, indicating an inhibitory effect on platelet precursor development.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Recombinant interferon-alpha (rIFN)-alpha is an established therapy for thrombocytosis.
- Previous studies suggest rIFN-alpha can suppress human megakaryopoiesis.
Purpose of the Study:
- To investigate the morphometric effects of rIFN-alpha-2c on megakaryopoiesis in patients with chronic myeloproliferative disorders.
- To evaluate changes in megakaryocyte density and size during rIFN-alpha-2c therapy.
Main Methods:
- Bone marrow biopsies were analyzed from 12 patients with thrombocytosis.
- Morphometric parameters of megakaryopoiesis were assessed before and during rIFN-alpha-2c treatment.
- Changes in megakaryocyte density, size, and nuclear morphology were quantified.
Main Results:
- A significant decrease in megakaryocyte density was observed across all patients.
- Megakaryocyte size decreased in polycythaemia vera, agnogenic myeloid metaplasia, and essential thrombocythaemia, but increased in chronic myeloid leukaemia.
- Increased pyknotic nuclei suggested a shortened megakaryocyte lifespan; bone marrow fiber content remained unchanged.
Conclusions:
- rIFN-alpha-2c exhibits an inhibitory effect on megakaryopoiesis.
- The therapy appears to selectively influence megakaryocytes at different maturation stages.
- These findings clarify the mechanism of rIFN-alpha in managing thrombocytosis through megakaryocyte modulation.